Focal adhesion remodeling is crucial for glucose-stimulated insulin secretion and involves activation of focal adhesion kinase and paxillin

Rondas, Dieter; Tomas, Alejandra; Halban, Philippe A.

How to cite

RONDAS, Dieter, TOMAS, Alejandra, HALBAN, Philippe A. Focal adhesion remodeling is crucial for glucose-stimulated insulin secretion and involves activation of focal adhesion kinase and paxillin. In: Diabetes, 2011, vol. 60, n° 4, p. 1146–1157. doi: 10.2337/db10-0946

This publication URL: https://archive-ouverte.unige.ch/unige:25378
Publication DOI: 10.2337/db10-0946

FOCAL ADHESION REMODELING IS CRUCIAL FOR GLUCOSE-STIMULATED INSULIN SECRETION AND INVOLVES ACTIVATION OF FOCAL ADHESION KINASE AND PAXILLIN

FOCAL ADHESION REMODELING IN INSULIN SECRETION

Dieter Rondas[1], Alejandra Tomas[1,2], Philippe A. Halban[1]

[1]Department of Genetic Medicine and Development, University Medical Center, University of Geneva, Geneva, Switzerland

[2] Present address: Department of Biochemistry, University of Geneva, Switzerland.

Address for all correspondence:

Dr. Dieter Rondas
Department of Genetic Medicine and Development
University Medical Center
1 rue Michel-Servet
1211 Geneva 4, Switzerland

Email: dieter.rondas@unige.ch

FAX: ++ 41 22 379 5528
Tel: ++ 41 22 379 5534

Word count abstract: 246
Word count main text: 3999
Number of tables: 1
Number of figures: 7

ABSTRACT

***Objective*:** Actin cytoskeleton remodeling is known to be involved in glucose-stimulated insulin secretion (GSIS). We have observed glucose-stimulated changes at the beta cell basal membrane similar to focal adhesion remodeling in cell migration. This led us to study the role of two key focal adhesion proteins, Focal Adhesion Kinase (FAK) and paxillin, in GSIS.

***Research Design and Methods*:** All studies were performed using rat primary beta cells or isolated islets. Protein phosphorylation and subcellular localization were determined by Western blotting and confocal immunofluorescence respectively. Insulin was measured by radioimmunoassay. Both siRNA and pharmacological approaches were used to assess the role of FAK and paxillin in glucose-stimulated focal adhesion remodeling and insulin secretion.

***Results*:** Glucose stimulation of beta cells in monolayer significantly increased phosphorylation of FAK and paxillin as well as cell surface area. This coincided with the appearance at the basal membrane of numerous shorter actin filopodial extensions, containing not only phosphorylated paxillin, FAK and ERK1/2 but also two SNARE proteins, SNAP-25 and syntaxin 1, indicating involvement in exocytosis. SR7037 completely inhibited this sequence of events, indicating the requirement of increased cytosolic Ca^{2+}. Furthermore, knockdown of paxillin significantly decreased GSIS as did inhibition of glucose-induced FAK phosphorylation by compound Y15. Key findings were confirmed in beta cells within the natural setting of islets.

***Conclusions*:** Glucose-stimulated remodeling of focal adhesions and phosphorylation of FAK and paxillin are involved in full development of GSIS, indicating a previously unknown role for focal adhesion remodeling in pancreatic beta cell function.

INTRODUCTION

Nearly 40 years ago, first studies indicated the presence of microfilamentous structures which impacted stimulated secretion in pancreatic beta cells (1; 2). Filamentous actin (F-actin) in beta cells was reported to be organized as a dense web beneath the plasma membrane (2) and was later shown to undergo remodeling upon glucose stimulation. In addition, others reported enhanced secretagogue-induced insulin secretion in the presence of F-actin disrupting agents (3-7). Taken together, these reports suggest F-actin remodeling as a key factor in insulin granule priming and mobilization through the F-actin web, but the underlying molecular mechanism and key signaling pathways involved in this process remain largely unknown.

Two-way signaling between a cell and its surrounding extracellular matrix (ECM) is highly important for actin cytoskeleton organization and thereby also for beta cell viability and function (8; 9). The majority of the cellular receptors involved in cell-matrix interactions belong to the integrin family (10). Studies on rat pancreatic beta cells revealed that α3β1 and α6β1 integrins are highly expressed on the cell surface (8; 11). In addition, both integrins are receptors for laminin-5, a component of ECM known to promote rat beta cell function and survival (8; 9). The integrin-mediated physical connection between cell and ECM is not simply mechanical but also results in the induction of outside-in integrin-dependent signaling pathways, beginning with tyrosine phosphorylation of the key cytoskeletal protein focal adhesion kinase (FAK) (12).

FAK is a non-receptor tyrosine kinase considered a central molecule in integrin-mediated signaling, involved in cell cycle progression, cell survival and migration (13). While the N-terminal domain of FAK is important for interaction with integrins (14), the carboxyl-terminal tyrosine (Y) 397 residue constitutes a major phoshorylation site located in a linker region

connecting the regulatory and central kinase domain. In the inactivated state this site and the Src recruitment site, located in the activation loop, are blocked by the regulatory domain, preventing autophosphorylation of Y397 and the ensuing Src-mediated phosphorylation of the activation loop (15). While the precise mechanisms that allow Y397-autophosphorylation and subsequent steps in FAK activation are not clear, interaction with Src results in phosphorylation of multiple other FAK tyrosine residues, as well as other focal complex-associated proteins including $p130^{CAS}$ and paxillin (16-20). These and several other proteins are, upon integrin engagement with the ECM, constantly recruited to/removed from and activated/deactivated in dynamic signaling structures named focal adhesions (FAs). This eventually results in cytoskeletal changes and activation of other downstream signaling cascades such as the phosphatidylinositol 3-kinase (PI3-K), Akt, extracellular signal-regulated kinase 1/2 (ERK1/2) and mitogen-activated protein kinase (MAPK) (21) pathways.

In the present study, we show that activated FAK-paxillin complexes are incorporated into nascent FAs upon glucose stimulation of primary rat beta cells. FA remodeling in response to glucose is Ca^{2+}-dependent, rapid, reversible and linked to the short-term glucose-induced activation of the ERK1/2 signaling pathway. Finally, we show here for the first time that these glucose-mediated events are essential for regulated insulin secretion from beta cells, whether in monolayer cultures or within whole islets.

RESEARCH DESIGN AND METHODS

Reagents and antibodies.

The FAK inhibitor 1,2,4,5-benzenetetraamine tetrahydrochloride (Y15) was purchased from Sigma-Aldrich (St. Louis, MO, USA). To visualize F-actin, Alexa Fluor® 647-phalloidin was obtained from Invitrogen (Carlsbad, CA, USA). Primary antibodies (Ab): rabbit anti-FAK polyclonal (p)Ab, Santa Cruz Biotechnology (Santa Cruz, CA, USA); rabbit anti-phospho(Y397)FAK pAb and rabbit anti-phospho(Y118)paxillin pAb, Invitrogen; mouse anti-paxillin monoclonal (m)Ab, BD Transduction Laboratories (San Jose, CA, USA); rabbit anti-ERK1/2 pAb and rabbit anti-phospho(T202/Y204)ERK1/2 pAb, Cell Signaling Technology (Beverly, MA, USA); mouse anti-actin mAb, Millipore (Temecula, CA, USA). Secondary antibodies: donkey anti-rabbit horseradish peroxidase (HRP) and sheep anti-mouse HRP, Amersham Biosciences (Uppsala, Sweden); donkey anti-rabbit Alexa Fluor® 488 and donkey anti-mouse Alexa Fluor® 555, Invitrogen; AMCA-conjugated donkey anti-guinea pig, Jackson ImmunoResearch Laboratories (West Grove, PA, USA).

Primary rat beta cell purification and culture.

Rat islet isolation, beta cell sorting and monolayer culture on ECM from 804G cells (804G-ECM) were performed as previously described (22). Intact islets were first maintained for 24 h and then studied in suspension culture.

RNAi-mediated silencing of paxillin.

Paxillin expression was depleted by transfecting primary rat beta cells twice with a pool of three different siRNAs (5'-UGGCACAGUCCUGGACCCCTT-3', 5'-CCUCUCUGAGCUGGACCGGTT-3' and 5'-GACAUGGCACCCCGAGCACTT-3' from Microsynth AG, Balgach, Switzerland) directed against rat paxillin mRNA using

Lipofectamine™ 2000 reagent (Invitrogen) according to the manufacturer's instructions. Transfected cells were incubated for 72 h to allow for siRNA expression before analysis.

SDS-PAGE and Western blotting.

SDS-PAGE and Western blotting were performed as previously described (5).Western blots were incubated with the ECL Plus Western Blotting detection system (Amersham Biosciences) and exposed with the Fujifilm LAS-4000 camera system. Protein band intensities were quantified by densitometry using the Multi Gauge v3.0 software.

Immunofluorescence and confocal microscopy.

Immunofluorescence and confocal microscopy on sorted beta cells in monolayer were performed as previously described (5). Isolated rat islets were washed in PBS and fixed in 2% paraformaldehyde, dehydrated, embedded in paraffin and sectioned at 5 µm. Before immunofluorescence, sections were deparaffinized and rehydrated with a series of alcohol solutions of decreasing concentration. Primary antibodies (guinea pig anti-insulin, rabbit anti-phosphopaxillin and mouse anti-actin) and secondary antibodies (AMCA-conjugated anti-guinea pig, Alexa 488-conjugated anti-rabbit and Alexa 555-conjugated anti-mouse) were diluted in PBS-0.5% BSA and incubations were performed at room temperature.

Insulin secretion assays.

Insulin secretion assays were performed as previously described (5).

TUNEL assay.

Cell death was measured as previously described (23).

Statistical analyses.

The statistical significance of the differences between the experimental conditions was determined by Student's *t* test for unpaired groups. *P* values less than 0.05 were considered significant.

RESULTS

Aside from experiments using intact islets when indicated, all studies were performed using sorted rat primary beta cells cultured in monolayer on a surface coated with 804G-ECM (22).

FAK, paxillin and ERK1/2 are activated upon glucose stimulation of rat primary beta cells.

In order to gain insight into a possible role of FAK and two of its downstream targets paxillin and ERK1/2 in glucose-regulated beta cell function, we studied the phosphorylation status of these proteins in response to glucose. Phosphorylation of both FAK (Y397) and paxillin (Y118) was already detectable under basal conditions but was significantly increased following glucose stimulation (20 min) indicating short-term glucose-mediated activation of these two FA factors. A similar effect was observed for ERK1/2 (Fig. 1*A* and *B*).

A previous study in the mouse pancreatic beta cell line MIN6B1 documented the rapid glucose-stimulated activation of ERK1/2 and subcellular localization of active phosphoERK1/2 at newly formed tips of actin fibres (5). Based on these observations we used the ERK1/2 inhibitor PD98059 to determine whether ERK1/2 is implicated in the short-term glucose-induced phosphorylation of FAK and paxillin. Fig. 1*C* clearly indicates the inhibitory effect of PD98059 on the phosphorylation of both FA proteins.

Activated FAK, paxillin and ERK1/2 co-localize in actin filopodial extensions upon glucose stimulation.

To determine the main sites of action of phosphorylated FAK and paxillin, we analyzed the subcellular localization of the respective activated proteins in conjunction with the F-actin cytoskeleton by confocal immunofluorescence of the basal cell surface (defined as the cell membrane in direct contact with ECM). In beta cells pre-incubated for 2 h at 2.8 mM glucose,

phosphorylated paxillin localized in few long filopodial extensions (Fig. 2*A* left panel, 2.8 mM glucose). Upon short-term glucose stimulation, there was actin cytoskeleton reorganization coinciding with the striking accumulation of phosphopaxillin at the tips of numerous newly formed, shorter filopodia, resembling classical nascent FAs (Fig. 2*A* left panel, 16.7 mM glucose). Similar morphological changes were apparent following stimulation with KCl, PMA or GLP-1 (data not shown). Quantification of these phosphopaxillin-containing FAs showed a significant increase in FA density in response to glucose stimulation (Fig. 2*A* right panel). When such glucose-stimulated beta cells were shifted back to low glucose, they regained their basal conformation within 20 min (Fig. 2*B*), indicating the dynamic, reversible character of the glucose-mediated formation of FAs. Shorter stimulations of 5 or 10 min at 16.7 mM glucose resulted in similar changes, indicating the rapid time course of this glucose-induced remodeling process (data not shown).

Further analysis of these filopodial extensions of glucose-stimulated beta cells revealed the co-localization of activated phosphoFAK (Fig 2*C*, lower panels) and phosphoERK1/2 (Fig 2*C*, upper panels) along with paxillin, indicating that the previously described sites of short-term glucose-dependent ERK1/2 activation at the tips of actin fibres (5) correspond to the nascent FAs formed in response to glucose. Moreover, (co-)localization of phosphopaxillin with two SNARE proteins, SNAP-25 and syntaxin 1, at these glucose-induced filopodial extensions (Fig. 2*D*) suggested a functional role for these sites in regulated insulin secretion.

Short-term glucose-stimulated beta cell spreading coincides with focal adhesion remodeling.

Rat islet beta cells attached on ECM spread in response to high glucose over 24 h (8). To assess the effect of acute exposure, beta cells were stimulated for 10, 20, 40 and 60 min with

high glucose and cell surface was measured. As shown in Fig. 3*A*, there was already a significant increase in spreading after 20 min with a further increase at 60 min. Furthermore, 3-dimensional reconstruction of confocal stack images clearly illustrates that glucose-stimulated cell spreading is accompanied by the appearance of the phosphopaxillin-containing filopodial extensions described earlier (Fig. 3*B*).

Glucose-stimulated Ca^{2+} influx is required for activation and translocation of FAK and paxillin.

A selective blocker of voltage-gated Ca^{2+} channels, SR7037, was used to establish the need for increased cytosolic Ca^{2+} in glucose-induced FA remodeling and FAK, paxillin and ERK1/2 activation. Having confirmed the previously described inhibitory effect of SR7037 on GSIS (22) (data not shown) we demonstrated that SR7037 markedly decreased short-term glucose-stimulated formation of phosphopaxillin-containing filopodial extensions (Fig. 4*A,* left panel) which was validated by quantification of these structures (Fig. 4*A,* right panel). Furthermore, Western blot analysis revealed that glucose-induced phosphorylation of FAK, paxillin and ERK1/2 was inhibited by SR7037 (Fig. 4*B*).

FAK inhibition reduces glucose-stimulated focal adhesion remodeling and insulin secretion.

In view of the important role for proteins such as FAK and paxillin in ECM-integrin-actin cytoskeleton interactions and the data presented above, we hypothesized that the activated FAK-paxillin-ERK1/2 complexes located at the newly formed filopodia might mediate GSIS. To test this hypothesis, we first examined whether FAK activation represents a regulatory step in glucose-stimulated phosphorylation of paxillin and ERK1/2, using compound Y15, which specifically inhibits FAK-Y397 autophosphorylation (24; 25). As shown in Fig. 5*A*, glucose-

induced phosphorylation of FAK, paxillin, and ERK1/2 is significantly inhibited by Y15. This indicates that glucose-induced activation of ERK1/2 is at least partially dependent on FAK activation while we showed above that the opposite is also true, with FAK activation being inhibited by the ERK1/2 inhibitor PD98059. These two observations are compatible with earlier evidence of ERK1/2 acting both up- and downstream of FAK in FA remodeling (26; 27).

Immunofluorescence experiments revealed that treatment with Y15 resulted in a marked reduction in glucose-induced translocation and incorporation of phosphopaxillin in newly formed short FAs (data not shown) which was confirmed by quantification of the latter (Fig. 5*B*). Furthermore, Y15 significantly decreased short-term glucose-induced beta cell spreading (Fig. 5*C*).

Finally, we investigated the effect of inhibition of FAK phosphorylation on GSIS. In the presence of compound Y15, insulin secretion in response to glucose was decreased by 76.9±5.4% ($P < 0.001$), whereas basal secretion was 4.4-fold increased (from 0.16±0.02 to 0.72±0.20%, $P < 0.05$) (Fig. 5*D*). This decrease was sustained throughout both early (corresponding to first phase) and late (second phase) periods of the stimulatory period (Fig. 5*E*). There was also a 27.3±8.4% ($P < 0.05$) decrease in the total (secreted + intracellular) insulin content after compound Y15 treatment (data not shown) which might explain the increase in basal insulin secretion (as a fraction of cell content). The Y15-mediated inhibition of glucose-induced FA formation was reversible (Fig 5*F,* upper panel) and this was attended by the partial recovery of GSIS (Fig 5*F,* lower panel).

RNAi-mediated knockdown of FAK and paxillin inhibits glucose-stimulated insulin secretion.

Although inhibition of FAK activation by Y15 indicated its involvement in FA remodeling and insulin secretion in response to glucose, there is always the risk of unexpected non-specific or off-target effects when using pharmacological agents. We used two different strategies to overcome this. For the first approach, RNAi-mediated silencing of FAK was performed in MIN6 B1 cells, resulting in a ~40% reduction in the level of FAK which was associated with a 40.2±2.3 % ($P < 0.001$) decrease in GSIS (data not shown).

The second series of experiments involved knockdown of paxillin in primary rat beta cells using siRNA duplexes. We have shown previously that siRNA duplexes can be successfully introduced into the vast majority of primary beta cells using standard transfection procedures (28). Paxillin knockdown (Fig. 6*A*) did not affect beta cell death (Fig. 6*B*) but did, similar to Y15, result in a significant inhibition of glucose-induced ERK1/2-phosphorylation (Fig. 6*C*), FA formation (Fig. 6*D*) and beta cell spreading (Fig. 6*E*). Furthermore, silencing of paxillin also decreased GSIS by 60.0±5.7% ($P < 0.05$) (Fig. 6*F*). However in contrast to Y15, paxillin knockdown did not affect total insulin content (data not shown) nor basal secretion. Finally, Table 1 illustrates that silencing of paxillin also significantly inhibited KCl-, PMA- and GLP-1-stimulated insulin secretion.

Focal adhesion remodeling in intact rat islets.

As all the former experiments were performed using sorted beta cells in two-dimensional (2D) monolayer culture on 804G-ECM, a less physiological setting than that of the three-dimensional (3D) micro-organ, we also verified beta cell behavior within intact islets. A single preliminary experiment confirmed glucose-induced phosphorylation of FAK at Y397

that was inhibited by treatment of the islets with compound Y15. However, short-term glucose-stimulation did not result in increased phosphorylation of paxillin nor ERK1/2 (data not shown). Furthermore, and most significantly, 3D-reconstruction of immunofluorescence confocal stack images of semi-thin sections of differently treated intact islets (Fig 7*A*) revealed the glucose-induced concentration of phosphopaxillin in well-defined patches. This glucose-induced effect was inhibited by treatment of the islets with compound Y15 (Fig. 7*A* right hand images). The FA-like filopodial extensions and actin stress fibres observed in 2D beta cell monolayers in response to glucose were not seen in intact islets but this was anticipated for cells in such a 3D configuration (discussed further below). Finally, we observed that FAK-inhibition resulted in a significant decrease (64.5±16.4%; $P < 0.05$) in GSIS from whole islets (Fig. 7*B*). Taken together, these results suggest that notwithstanding the anticipated differences in glucose-induced physical alterations in beta cells in 2D monolayers vs. whole islets, FAK-signaling also appears to play an important role in regulated insulin secretion from beta cells present in the more physiological setting of the 3D micro-organ.

DISCUSSION

Cellular attachment, spreading and migration involve FA remodeling (29) that is associated with reorganization of cytoskeletal structures and activation of intracellular signaling pathways. Focal contact sites thereby provide both a structural link between the ECM and cytoskeletal proteins as well as initiation points for outside-in signaling leading to changes in cell activity and gene expression (30-32). In the present study we describe short-term glucose-stimulated changes at the beta cell basal membrane that are reminiscent of FA remodeling at filopodia during cell migration, and show these to be involved in GSIS.

Both FAK and paxillin have been identified as FA proteins that become phosphorylated in response to ECM adhesion (33).

The best-characterized FAK phosphorylation event is Y397-autophosphorylation, crucial for its kinase activity (34). Regarding paxillin, Y118 has been shown to be the major tyrosine-phosphorylation site involved in focal contacts turnover and cell motility (20; 35). The observation that short-term glucose stimulation of beta cells induces increased phosphorylation of FAK and paxillin at these particular sites thus indicates a possible role for these proteins in beta cell function.

Translocation of FAK and paxillin into FAs has been found to be critical for cell spreading and migration, but not for cell adhesion (36; 37). In epithelial cells induced to migrate, immunolabelling with phosphotyrosine antibodies revealed that phosphopaxillin was mainly localized along the cell periphery and connected to actin stress fibres in FAs (38). In agreement with these findings we observed, prior to cell spreading, the glucose-induced formation of multiple, nascent FAs containing both phosphorylated FAK (Y397) and paxillin (Y118) in close proximity. Furthermore, we confirmed the basal membrane-proximal

localization of phosphoERK1/2 at the tips of actin filaments in glucose-stimulated beta cells (5) and now demonstrate the co-localization of phosphoERK1/2 with paxillin at these particular sites that we define as filopodial FAs.

Glucose stimulation of beta cells results in an increase of intracellular Ca^{2+} that is known to be a key trigger for insulin secretion. SR7037, a selective L-type Ca^{2+} channel blocker, inhibited glucose-stimulated phosphorylation of ERK1/2, FAK and its substrate paxillin, showing these events to be dependent upon Ca^{2+} influx. This is in accordance with previous studies in other cell types reporting induced FAK autophosphorylation and kinase activity driven by a physiological rise in intracellular Ca^{2+} concentration (39-41). Moreover, earlier reported Ca^{2+}-dependent reversibility of FAK activation and cell spreading (40) coincides with the reversible character of the glucose-induced formation of nascent FAs in beta cells, suggesting an important role for Ca^{2+} in the dynamic regulation of cellular FAs during short-term glucose stimulation. These results, together with the previously described inhibitory effect of SR7037 on GSIS (22), suggest a so far unsuspected link between FA remodeling and regulated insulin secretion in beta cells. Note however that the observed changes in FAK and paxillin phosphorylation were small compared with the drastic inhibition of GSIS by SR7037, suggesting that the activation of FAK and paxillin is only partially Ca^{2+}-dependent and that this in combination with the inhibition of other Ca^{2+}-dependent ERK1/2 activation mechanisms by SR7037 results in a significant inhibition of ERK1/2 and GSIS.

To confirm the possible involvement of FAK in GSIS, we performed both RNAi-mediated FAK knockdown (in MIN6B1 cells) and pharmacological inhibition of FAK activity by compound Y15 (25). The latter was identified as a specific inhibitor of Y397-FAK phosphorylation by using a structure-based approach combining functional testing and

molecular docking of the 3D structure of numerous small molecule compounds into the structural pocket of the Y397-site. Specificity of this inhibitory compound has been further verified using various *in vitro* kinase assays (24). Both strategies demonstrated a link between the level and activity of FAK, FA remodeling, ERK1/2 pathway activation and GSIS in beta cells. We further confirm this by siRNA-mediated silencing of paxillin, resulting in a significant inhibition of glucose-induced ERK1/2 phosphorylation, FA formation, beta cell spreading and insulin secretion (without affecting total insulin content or cell survival). These results, in combination with the demonstrated co-localization of activated FAK, paxillin and ERK1/2 at filopodial FAs at the basal membrane of glucose-stimulated beta cells, indicate that glucose-induced FA remodeling plays a crucial role in GSIS. Furthermore, the inhibitory effect of paxillin knockdown on KCl-, PMA- and GLP-1-stimulated insulin secretion indicates that paxillin acts at a distal step in the insulin secretory machinery. A comparable inhibitory effect of compound Y15 on both the early and late phases of insulin secretion corroborates this but could also indicate that both the initial size of the readily releasable pool and the following supply of secretory vesicles to this pool are affected by blocking FAK activation. However, as it cannot be excluded by these experiments that paxillin RNAi also impacts insulin secretion by other, indirect ways e.g. by modulating expression of key beta cell genes, this is something that will need to be studied in the future.

In view of these observations, we propose that glucose-induced autophosphorylation and thereby activation of FAK is mediated by increased intracellular Ca^{2+} concentrations. Activated FAK then phosphorylates its direct substrate paxillin which may act as an adaptor protein through FAK to increase linkage between activated integrin complexes and the actin cytoskeleton. We hypothesize that these events and the coinciding actin cytoskeletal reorganization are essential for full development of GSIS, acting at a late stage in exocytosis.

This is supported by the (co-)localization of phosphopaxillin with SNAP-25 and syntaxin 1 in glucose-induced FAs as these two SNARE proteins are well known to play a pivotal role during vesicle fusion in the process of regulated insulin exocytosis with documented links to the beta cell actin cytoskeleton (4; 42). In addition, as observed in CHO-K1 cells (43), these data might also suggest a role for SNARE-mediated membrane trafficking in glucose-induced FA signaling in beta cells.

Our results also point towards the FAK-paxillin-complex as the mediator of actin remodeling–induced local phosphorylation of ERK1/2 at FAs after glucose stimulation of beta cells. FAK-Src-mediated tyrosine phosphorylation of paxillin is known to result in association of inactive ERK with its upstream effectors MEK and Raf forming a scaffold and facilitating ERK activation at FAs (27), offering a molecular basis for our own observations. This pathway is self-enhanced as activated ERK can then phosphorylate paxillin itself which will increase its association to FAK and in turn enhance FAK activation (26; 27), consistent with our data using the ERK1/2 inhibitor PD98059. This short-term ERK1/2-triggered phosphorylation of FAK and paxillin correlates with earlier studies showing that ERK1/2 is involved in early phase GSIS (5). Note however the differences in the level of glucose-induced phosphorylation between FAK/paxillin and ERK1/2 that confirm the involvement of additional signaling pathways in glucose-induced ERK1/2 activation. Glucose-activated ERK1/2 has been shown previously to be involved in the regulation of insulin secretion and coincides temporally with transient glucose-induced actin cytoskeleton remodeling (4; 5). In addition, activation of FAK and paxillin could also potentiate GSIS in beta cells through ERK1/2-mediated phosphorylation of synapsin 1 (44), a protein which is believed to function as a linker between the vesicle membrane and the actin cytoskeleton. Synapsin 1 phosphorylation may result in the release of secretory granules from the cytoskeleton network

and mobilization from a passive, reserve pool to an active, releasable pool (45). Further experiments outside the scope of this study will be required to verify this functional hypothesis.

To confirm our central hypothesis in the more physiological setting of the 3D micro-organ, additional experiments were performed on whole islets. These experiments revealed clear differences in behavior between cells in 2D culture and 3D aggregates. Beta cells within islets did not show clearly evident actin stress fibres and FAs were not present in filopodial extensions which was entirely expected, based on the comparison of these structures in other cell types in 2D versus 3D assemblies (46). However, glucose-induced phosphorylation of FAK and clearly changed phosphopaxillin subcellular localization in beta cells within islets which was prevented by compound Y15 that also inhibited GSIS from whole islets. In contrast, in a single preliminary experiment paxillin and ERK1/2 phosphorylation in whole islets were not affected by glucose. This could be due to opposite glucose-induced changes in other islet cell types or higher basal phosphorylation levels of both paxillin and ERK1/2 in islets compared to sorted beta cells. The latter could once again be explained by the mixed contribution of all islet cells in Western blots of whole islet proteins, but also possibly by the presence of glucagon secreted by alpha cells as ERK1/2 is a known substrate of PKA that would be activated by increased cAMP in response to glucagon (47). Finally, we cannot exclude that the 3D-organization of cells within islets impacts on the phosphorylation of these proteins involved in inside-out and outside-in cell signaling.

In conclusion, the present study shows for the first time the existence of short-term glucose-mediated, Ca^{2+}-dependent activation of the key FA proteins, FAK and paxillin in pancreatic beta cells. Most importantly, this FA remodeling process appears to be an important player in

GSIS, providing a novel additional component to the complex molecular machinery underlying this key event in glucose homeostasis. Despite the well recognized differences in behavior between beta cells in 2D culture and whole islets it was reassuring to be able to confirm the most important features of this novel component of beta cell regulated exocytosis using intact islets. Further studies are needed to determine the exact molecular events downstream of glucose-induced activation of FAK and paxillin that impact on insulin secretion and whether perturbation of this new pathway contributes towards beta cell dysfunction in type 2 diabetes.

AUTHOR CONTRIBUTIONS

D.R. Researched data, contributed to discussion, wrote manuscript, reviewed/edited manuscript.

A.T. Researched data, contributed to discussion, reviewed/edited manuscript.

P.H. Contributed to discussion, reviewed/edited manuscript.

ACKNOWLEDGMENTS

This work was supported by Grant number 31003A_127276/1 from the Swiss National Science Fund and by an unrestricted educational grant from GlaxoSmithKline. We are greatly indebted to Ms. Katharina Rickenbach and Mr. Stéphane Dupuis (University of Geneva) for expert technical assistance.

REFERENCES

1. Malaisse WJ, Malaisse-Lagae F, Walker MO, Lacy PE: The stimulus-secretion coupling of glucose-induced insulin release. V. The participation of a microtubular-microfilamentous system. *Diabetes* 20:257-265, 1971
2. Orci L, Gabbay KH, Malaisse WJ: Pancreatic beta-cell web: its possible role in insulin secretion. *Science* 175:1128-1130, 1972
3. Nevins AK, Thurmond DC: Glucose regulates the cortical actin network through modulation of Cdc42 cycling to stimulate insulin secretion. *Am J Physiol Cell Physiol* 285:C698-710, 2003
4. Thurmond DC, Gonelle-Gispert C, Furukawa M, Halban PA, Pessin JE: Glucose-stimulated insulin secretion is coupled to the interaction of actin with the t-SNARE (target membrane soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein) complex. *Mol Endocrinol* 17:732-742, 2003
5. Tomas A, Yermen B, Min L, Pessin JE, Halban PA: Regulation of pancreatic beta-cell insulin secretion by actin cytoskeleton remodelling: role of gelsolin and cooperation with the MAPK signalling pathway. *J Cell Sci* 119:2156-2167, 2006
6. Jewell JL, Luo W, Oh E, Wang Z, Thurmond DC: Filamentous actin regulates insulin exocytosis through direct interaction with Syntaxin 4. *J Biol Chem* 283:10716-10726, 2008
7. Tsuboi T, da Silva Xavier G, Leclerc I, Rutter GA: 5'-AMP-activated protein kinase controls insulin-containing secretory vesicle dynamics. *J Biol Chem* 278:52042-52051, 2003
8. Bosco D, Meda P, Halban PA, Rouiller DG: Importance of cell-matrix interactions in rat islet beta-cell secretion in vitro: role of alpha6beta1 integrin. *Diabetes* 49:233-243, 2000
9. Hammar E, Parnaud G, Bosco D, Perriraz N, Maedler K, Donath M, Rouiller DG, Halban PA: Extracellular matrix protects pancreatic beta-cells against apoptosis: role of short- and long-term signaling pathways. *Diabetes* 53:2034-2041, 2004
10. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. *Cell* 69:11-25, 1992
11. Kantengwa S, Baetens D, Sadoul K, Buck CA, Halban PA, Rouiller DG: Identification and characterization of alpha 3 beta 1 integrin on primary and transformed rat islet cells. *Exp Cell Res* 237:394-402, 1997
12. Mitra SK, Hanson DA, Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. *Nat Rev Mol Cell Biol* 6:56-68, 2005
13. Hauck CR, Hsia DA, Puente XS, Cheresh DA, Schlaepfer DD: FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. *Embo J* 21:6289-6302, 2002
14. Schaller MD, Otey CA, Hildebrand JD, Parsons JT: Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. *J Cell Biol* 130:1181-1187, 1995
15. Lietha D, Cai X, Ceccarelli DF, Li Y, Schaller MD, Eck MJ: Structural basis for the autoinhibition of focal adhesion kinase. *Cell* 129:1177-1187, 2007
16. Richardson A, Malik RK, Hildebrand JD, Parsons JT: Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: a role for paxillin tyrosine phosphorylation. *Mol Cell Biol* 17:6906-6914, 1997
17. Bellis SL, Miller JT, Turner CE: Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase. *J Biol Chem* 270:17437-17441, 1995
18. Schaller MD, Parsons JT: pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk. *Mol Cell Biol* 15:2635-2645, 1995

19. Cary LA, Han DC, Polte TR, Hanks SK, Guan JL: Identification of p130Cas as a mediator of focal adhesion kinase-promoted cell migration. *J Cell Biol* 140:211-221, 1998
20. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF: FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. *Nat Cell Biol* 6:154-161, 2004
21. Zhao J, Guan JL: Signal transduction by focal adhesion kinase in cancer. *Cancer Metastasis Rev* 28:35-49, 2009
22. Bosco D, Gonelle-Gispert C, Wollheim CB, Halban PA, Rouiller DG: Increased intracellular calcium is required for spreading of rat islet beta-cells on extracellular matrix. *Diabetes* 50:1039-1046, 2001
23. Yermen B, Tomas A, Halban PA: Pro-survival role of gelsolin in mouse beta-cells. *Diabetes* 56:80-87, 2007
24. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG: A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. *J Med Chem* 51:7405-7416, 2008
25. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, Golubovskaya VM: A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. *Cell Cycle* 8:2435-2443, 2009
26. Liu ZX, Yu CF, Nickel C, Thomas S, Cantley LG: Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. *J Biol Chem* 277:10452-10458, 2002
27. Ishibe S, Joly D, Zhu X, Cantley LG: Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis. *Mol Cell* 12:1275-1285, 2003
28. Bouzakri K, Ribaux P, Halban PA: Silencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects beta cells from tumor necrosis factor-alpha-induced decrease of IRS-2 and inhibition of glucose-stimulated insulin secretion. *J Biol Chem* 284:27892-27898, 2009
29. Smilenov LB, Mikhailov A, Pelham RJ, Marcantonio EE, Gundersen GG: Focal adhesion motility revealed in stationary fibroblasts. *Science* 286:1172-1174, 1999
30. Plopper GE, McNamee HP, Dike LE, Bojanowski K, Ingber DE: Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex. *Mol Biol Cell* 6:1349-1365, 1995
31. Miyamoto S, Teramoto H, Coso OA, Gutkind JS, Burbelo PD, Akiyama SK, Yamada KM: Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. *J Cell Biol* 131:791-805, 1995
32. Juliano RL, Haskill S: Signal transduction from the extracellular matrix. *J Cell Biol* 120:577-585, 1993
33. Burridge K, Turner CE, Romer LH: Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. *J Cell Biol* 119:893-903, 1992
34. Parsons JT: Focal adhesion kinase: the first ten years. *J Cell Sci* 116:1409-1416, 2003
35. Subauste MC, Pertz O, Adamson ED, Turner CE, Junger S, Hahn KM: Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. *J Cell Biol* 165:371-381, 2004
36. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. *Nature* 377:539-544, 1995
37. Hagel M, George EL, Kim A, Tamimi R, Opitz SL, Turner CE, Imamoto A, Thomas SM: The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling. *Mol Cell Biol* 22:901-915, 2002

38. Nakamura K, Yano H, Uchida H, Hashimoto S, Schaefer E, Sabe H: Tyrosine phosphorylation of paxillin alpha is involved in temporospatial regulation of paxillin-containing focal adhesion formation and F-actin organization in motile cells. *J Biol Chem* 275:27155-27164, 2000
39. Pelletier AJ, Bodary SC, Levinson AD: Signal transduction by the platelet integrin alpha IIb beta 3: induction of calcium oscillations required for protein-tyrosine phosphorylation and ligand-induced spreading of stably transfected cells. *Mol Biol Cell* 3:989-998, 1992
40. Alessandro R, Masiero L, Lapidos K, Spoonster J, Kohn EC: Endothelial cell spreading on type IV collagen and spreading-induced FAK phosphorylation is regulated by Ca2+ influx. *Biochem Biophys Res Commun* 248:635-640, 1998
41. Giannone G, Ronde P, Gaire M, Beaudouin J, Haiech J, Ellenberg J, Takeda K: Calcium rises locally trigger focal adhesion disassembly and enhance residency of focal adhesion kinase at focal adhesions. *J Biol Chem* 279:28715-28723, 2004
42. Sadoul K, Lang J, Montecucco C, Weller U, Regazzi R, Catsicas S, Wollheim CB, Halban PA: SNAP-25 is expressed in islets of Langerhans and is involved in insulin release. *J Cell Biol* 128:1019-1028, 1995
43. Skalski M, Sharma N, Williams K, Kruspe A, Coppolino MG: SNARE-mediated membrane traffic is required for focal adhesion kinase signaling and Src-regulated focal adhesion turnover. *Biochim Biophys Acta* 1813:148-158, 2011
44. Longuet C, Broca C, Costes S, Hani EH, Bataille D, Dalle S: Extracellularly regulated kinases 1/2 (p44/42 mitogen-activated protein kinases) phosphorylate synapsin I and regulate insulin secretion in the MIN6 beta-cell line and islets of Langerhans. *Endocrinology* 146:643-654, 2005
45. Matsumoto K, Ebihara K, Yamamoto H, Tabuchi H, Fukunaga K, Yasunami M, Ohkubo H, Shichiri M, Miyamoto E: Cloning from insulinoma cells of synapsin I associated with insulin secretory granules. *J Biol Chem* 274:2053-2059, 1999
46. Hakkinen KM, Harunaga JS, Doyle AD, Yamada KM: Direct Comparisons of the Morphology, Migration, Cell Adhesions, and Actin Cytoskeleton of Fibroblasts in Four Different Three-Dimensional Extracellular Matrices. *Tissue Eng Part A* 10.1089/ten.tea.2010.0273
47. Dalle S, Longuet C, Costes S, Broca C, Faruque O, Fontes G, Hani EH, Bataille D: Glucagon promotes cAMP-response element-binding protein phosphorylation via activation of ERK1/2 in MIN6 cell line and isolated islets of Langerhans. *J Biol Chem* 279:20345-20355, 2004

TABLE 1. Inhibitory effect of Pax RNAi on insulin secretion from rat primary beta cells in response to various secretagogues

Glucose (mM)	Secretagogues	Time (min)	Stimulated secretion Scr RNAi (%)	Stimulated secretion Pax RNAi (%)	Decrease in stimulated insulin secretion by Pax RNAi (%)	*P* value
5	-	60	0.27±0.07	0.17±0.07	40.5 ± 8.8	0.01
5	100 nM GLP-1	60	2.12±0.74	1.32±0.47	36.3 ± 4.8	0.002
2.8	30 mM KCl	20	0.27±0.08	0.12±0.04	55.3 ± 2.3	2.10^{-5}
2.8	100 nM PMA	60	1.45±0.52	1.12±0.53	30.3 ± 9.5	0.02

siRNA-transfected primary rat beta cells were pre-incubated under basal conditions (2.8 mM glucose) and subsequently incubated for 1 h with 2.8 mM glucose followed by either 1 h with 5 mM glucose, GLP-1 (+ 5 mM glucose) or PMA (+ 2.8 mM glucose) or 20 min with KCl (+ 2.8 mM glucose). Secretion is expressed as percentage of total insulin (secreted + cell content) and % decrease in stimulated insulin secretion compared to scrambled siRNA-transfected cells. Data are mean ± SEM from 3-4 independent experiments.

FIGURE LEGENDS

FIG. 1. High glucose stimulation potentiates FAK, paxillin and ERK1/2 phosphorylation in primary rat beta cells and is inhibited by the ERK1/2 inhibitor, PD98059. *A*: Rat beta cells were pre-incubated for 2 h in the presence of low glucose (2.8 mM) and were further treated for 20 min with low (2.8 mM) or high (16.7 mM) glucose. Cells were then collected and lysates were analyzed by Western blot with the indicated antibodies. A representative blot from 6 independent experiments is shown. *B*: The relative intensities of the phosphorylated and total protein bands were quantified by densitometry and expressed as a ratio. Data presented as fold-increase in this ratio for 16.7 vs. 2.8 mM glucose are mean ± SEM from 6 independent experiments (*$P < 0.01$ and **$P < 0.05$). *C*: After a 2 h pre-incubation in the presence of low glucose with 10 μM PD98059 (or DMSO as a negative control), rat beta cells were stimulated for 20 min with high glucose with PD98059 (or DMSO). Cell lysates were analyzed by Western blot and the relative intensities of the phosphorylated and total protein bands were quantified by densitometry and expressed as a ratio. Ratios were normalized to control high glucose-stimulated cells. Data are mean ± SEM from 3 independent experiments (*$P < 0.0001$ and **$P < 0.01$).

FIG. 2. High glucose results in the accumulation of phosphoFAK, phosphopaxillin and phosphoERK1/2 at newly formed focal adhesions in primary rat beta cells. *A*, left panel: Rat beta cells were pre-incubated for 2 h in the presence of low glucose (2.8 mM) and were further treated for 20 min with low (2.8 mM) or high (16.7 mM) glucose. Cells were subsequently fixed and stained for phosphopaxillin (green), total paxillin (red) and actin (with phalloidin, blue). Right panel: Quantification of phosphopaxillin-containing focal adhesions in low vs. high glucose conditions. Data are expressed as number of focal adhesions per μm of cell perimeter and are mean ± SEM from 4 independent experiments (*$P < 0.0001$). *B*: After pre-incubation for 2 h with 2.8 mM glucose, rat beta cells were incubated for 20 min with 2.8 mM glucose (upper panel), stimulated for 20 min with 16.7 mM glucose (middle panel) or stimulated for 20 min with 16.7 mM glucose and shifted back to 2.8 mM glucose for 20 min (lower panel). Cells were fixed and stained for phosphopaxillin (green) and actin (blue). *C*: Rat beta cells were pre-incubated for 2 h in the presence of low glucose (2.8 mM) and were then stimulated for 20 min with 16.7 mM glucose. Cells were fixed and stained with the indicated antibodies. Parts of the merged images (red boxes) are shown at higher magnification (right panels) to clearly visualize the presence of paxillin (red) with

phosphoFAK and phosphoERK1/2 respectively (green) in actin-containing filopodia (blue). White regions indicate co-localization. *D*: Cells were treated as described above and were stained with the indicated antibodies. All images are fully representative of 3-4 independent experiments.

FIG. 3. Glucose-stimulated focal adhesion remodeling is accompanied by progressive beta cell spreading. *A*: Rat primary beta cells were pre-incubated for 2 h with 2.8 mM glucose and then stimulated with 16.7 mM glucose. Cells were fixed at the indicated times, stained with Evans blue and cell surface areas were quantified using AxioVision®4.7.2. Data are mean ± SEM from 4 independent experiments; $*P < 0.05$ and $**P < 0.01$ vs. control cells kept at 2.8 mM glucose (0 min). *B*: Rat primary beta cells were pre-incubated for 2 h with 2.8 mM glucose and then treated for 20 min with 2.8 mM or 16.7 mM glucose. Cells were then fixed and stained for phosphopaxillin (green) and actin (red). Nuclei (blue) were stained with Hoechst 33342. 3D reconstructions from confocal image stacks were performed using Imaris®v4.0. Pictures are representative of multiple images from a single experiment.

FIG. 4. SR7037, a selective L-type Ca^{2+} channel blocker, decreases glucose-induced focal adhesion remodeling and glucose-stimulated phosphorylation of FAK, paxillin and ERK1/2 in primary rat beta cells. *A,* left panel: Rat beta cells were pre-incubated for 2 h in the presence of low glucose (2.8 mM) and were further stimulated for 20 min with high (16.7 mM) glucose with 1 μM SR7037 (or DMSO as a negative control). Cells were fixed and stained for phosphopaxillin (green), total paxillin (red) and actin (with phalloidin, blue). All images are fully representative of 3 independent experiments. Right panel: Quantification of phosphopaxillin-containing focal adhesions. Data are expressed as number of focal adhesions per μm of cell perimeter normalized to control high glucose-stimulated cells and are mean ± SEM from 3 independent experiments; $*P < 0.001$ vs. control stimulated cells. *B*: Rat beta cells were treated as described above. Cell lysates were analysed by Western blot with the indicated antibodies and relative intensities of the phosphorylated and total protein bands were quantified by densitometry and expressed as a ratio. Ratios were normalized to control high glucose-stimulated cells. Data are mean ± SEM from 3 independent experiments ($*P < 0.0001$ and $**P < 0.05$).

FIG. 5. Effect of FAK inhibition on focal adhesion remodeling and insulin secretion in primary beta cells. *A*: Rat beta cells were pre-incubated for 2 h in the presence of low glucose

(2.8 mM) with Y15 (1 μM, or DMSO) and were further stimulated for 20 min with high (16.7 mM) glucose in the presence of Y15 (1 μM, or DMSO). Cell lysates were analysed by Western blot with the indicated antibodies and the relative intensities of the phosphorylated and total protein bands were quantified by densitometry and expressed as a ratio. Ratios were normalized to control high glucose-stimulated cells. Data are mean ± SEM from 3 independent experiments (*$P < 0.001$ and **$P < 0.01$). *B*: Quantification of phosphopaxillin-containing focal adhesions in primary beta cells after 20 min stimulation with 16.7 mM glucose with or without 1 μM compound Y15. Data are expressed as number of focal adhesions per μm of cell perimeter normalized to control high glucose-stimulated cells and are mean ± SEM from 3 independent experiments; *$P < 0.01$ vs. control stimulated cells. *C*: Beta cells were incubated for 2 h with 2.8 mM glucose with compound Y15 (or DMSO) and then stimulated for 20 min with 16.7 mM glucose with or without compound Y15. Cells were then fixed and stained with Evans blue and cell surface areas were quantified using AxioVision®4.7.2. Cell areas were normalized to control high glucose-stimulated cells. Data are expressed as mean ± SEM from 3 independent experiments; *$P < 0.01$ vs. control stimulated cells. *D*: Rat primary beta cells were pre-incubated for 2 h with 2.8 mM glucose with compound Y15 (or DMSO). Cells were then incubated with low (2.8 mM, basal) followed by high (16.7 mM, stimulated) glucose with or without Y15 for 1 h. Insulin secretion is expressed as a percentage of total insulin cell content. Data are mean ± SEM from 3 independent experiments; *$P < 0.001$ and **$P < 0.05$ vs. control at same glucose concentration. *E*: Cells were incubated as described above but were stimulated with high glucose with Y15 (or DMSO) for the indicated times. Data are expressed as mean ± SEM from 4 independent experiments; *$P < 0.05$ vs. Y15-treated cells. *F*: Rat beta cells were pre-incubated for 2h with 2.8 mM glucose with or without compound Y15 (Pre-incubation conditions). Cells were then stimulated with 16.7 mM glucose with or without Y15 (Stimulation conditions). Upper panel: Cells were fixed and phosphopaxillin-containing focal adhesions were quantified and expressed as number per μm of cell perimeter normalized to control high glucose-stimulated cells. Lower panel: Insulin secretion is normalized to control high glucose-stimulated cells. Data are mean ± SEM from 3 independent experiments; *$P < 0.05$ and **$P < 0.001$.

FIG. 6. siRNA-mediated depletion of endogenous paxillin significantly attenuates glucose-stimulated focal adhesion remodeling and insulin secretion in primary rat beta cells. Beta cells were transfected with either scrambled siRNA or a cocktail of 3 siRNAs specific for rat

paxillin and studied 72 h later. *A*: Paxillin knockdown was verified by Western blot with equal loading confirmed with an anti-actin antibody. A representative blot from 3 independent experiments is depicted (left) and paxillin:actin ratios were quantified by densitometry (right). *B*: Cell death (apoptosis + necrosis) measured using the TUNEL assay. *C*: siRNA-transfected beta cells were incubated for 2 h with 2.8 mM glucose and stimulated for 20 min with 16.7 mM glucose. Lysates were analysed by Western blot with the indicated antibodies and the relative intensities of the phosphorylated and total protein bands were quantified by densitometry and expressed as a ratio. Ratios were normalized to scrambled siRNA-transfected cells. *D-E*: siRNA-transfected beta cells were incubated as described above. Cells were then fixed and stained with either phosphopaxillin and actin or Evans blue. Both phosphopaxillin-containing focal adhesions and cell surface areas were quantified and normalized to scrambled siRNA-transfected cells. *F*: siRNA-transfected primary beta cells were incubated with low (2.8 mM) followed by high (16.7 mM) glucose for 1 h and insulin release was monitored and expressed as a percentage of total cell content. Data are mean ± SEM from 3 independent experiments; **P* < 0.05 and **P < 0.001 vs. scrambled siRNA-transfected cells.

FIG. 7. Effect of FAK inhibition on insulin secretion and subcellular localisation of phosphopaxillin in beta cells in intact rat islets. *A*: Isolated islets were incubated for 2 h with 2.8 mM glucose with or without 1 μM Y15 and were then stimulated for 20 min with 2.8 mM glucose, 16.7 mM glucose or 16.7 mM glucose with Y15. Islet sections (5 μm) were then fixed and stained with the indicated antibodies. 3D reconstruction from confocal image stacks was performed using Imaris®v7.2. The upper 3 rows illustrate a top view and the lower row a side view of reconstructions of the same set of stacks from a single islet section for each given condition. In the side view images, actin-staining (red) is represented by reconstructed isosurfaces. Scale bars = 2 μm. Images are representative of multiple sections from 2 independent experiments. *B*: Isolated islets were first pre-incubated for 2 h at 2.8 mM glucose and then incubated for 1 h each at 2.8 mM followed by 16.7 mM glucose in the continued presence of 1 μM compound Y15 (or DMSO). Islets were then incubated with low (2.8 mM, basal) followed by high (16.7 mM, stimulated) glucose with or without Y15 for 1 h. Insulin secretion is expressed as a percentage of total insulin cell content, normalized to control stimulated islets. Data are mean ± SEM from 3 independent experiments; **P* < 0.05 vs. control stimulated islets.


A
Glucose (mM)
2.8
16.7
p-FAK (Y397)
FAK
2.8
16.7
p-paxillin (Y118)
paxillin
2.8
16.7
p-ERK (T202/Y204)
ERK
B
2.8 mM Glucose
16.7 mM Glucose
Phospho-FAK:Total FAK [Fold Increase]
Phospho-pax:Total pax [Fold Increase]
Phospho-ERK:Total ERK [Fold Increase]
C
16.7 mM Glucose
16.7 mM Glucose + 10 µM PD98059
Phospho-FAK:Total FAK (%)
Phospho-pax:Total pax (%)
Phospho-ERK:Total ERK (%)


A
Glucose (mM)
2.8
16.7
20 μm
10 μm
p-paxillin
paxillin
actin
2.8 mM Glucose
16.7 mM Glucose
FAs per μm cell perimeter
B
time (min)
Glucose (mM)
20
2.8
20
16.7
20+20
16.7 ▶ 2.8
ppax
actin
D
Glucose (mM)
p-pax
syntaxin 1
actin
Merged
16.7
SNAP-25
C
p-ERK1/2
paxillin
Merged
Zoom
p-FAK
5 μm


A
14000
12000
10000
8000
6000
4000
2000
0
Cell area (a.u.)
*
**
0
10
20
60
Time (min)
B
Glucose (mM)
2.8
16.7
Top view
Side view


A
Glucose (mM)
SR7037 (μM)
16.7
0
16.7
1
10 μm
p-paxillin
paxillin
actin
16.7 mM Glucose
16.7 mM Glucose + 1 μM SR7037
FAs per μm cell perimeter (%)
120
100
80
60
40
20
0
*
B
16.7 mM Glucose
16.7 mM Glucose + 1 μM SR7037
Phospho-FAK:Total FAK (%)
Phospho-pax:Total pax (%)
Phospho-ERK:Total ERK (%)
*
**
*


A
16.7 mM Glucose
16.7 mM Glucose + 1 μM Y15
Phospho-FAK:Total FAK (%)
Phospho-pax:Total pax (%)
Phospho-ERK:Total ERK (%)
B
FAs per μm cell perimeter (%)
C
Cell area (%)
D
2.8 mM Glucose
16.7 mM Glucose
Insulin secretion (% of content)
Control
Y15
E
Control
1 μM Y15
Insulin secretion (% of content)
Stimulation time (min)
F
# of Fas per μm cell perimeter (%)
Insulin secretion (%)
Y15 (1 μM)
Preincubation
Stimulation


A
Paxillin
actin
Scr siRNA
Pax siRNA
Paxillin:actin (%)
120
100
80
60
40
20
0
**
Scr siRNA
Pax siRNA
B
TUNEL positive cells (%)
2.5
2
1.5
1
0.5
0
ns
Scr siRNA
Pax siRNA
C
Phospho-ERK:Total ERK (%)
150
100
50
0
*
Scr siRNA
Pax siRNA
D
Fas per µm cell perimeter (%)
120
100
80
60
40
20
0
**
Scr siRNA
Pax siRNA
E
Cell area (%)
120
100
80
60
40
20
0
*
Scr siRNA
Pax siRNA
F
2.8 mM Glucose
16.7 mM Glucose
Insulin secretion (% of content)
9
8
7
6
5
4
3
2
1
0
*
Scr siRNA
Pax siRNA


A
Glucose (mM)
2.8
16.7
16.7
Y15 (μM)
0
0
1
Insulin
phosphopaxillin
Actin
Merged
B
16.7 mM Glucose
16.7 mM Glucose
+ 1 μM Y15
Insulin secretion (%)
120
100
80
60
40
20
0
*